Asabys Partners, a European life sciences investment firm based in Madrid and Barcelona, has integrated Aliath Bioventures, formerly Alta Life Sciences, in a strategic $468 million consolidation. This merger boosts Asabys’ assets under management from $351 million to over $468 million, paving the way toward a goal of exceeding €1 billion by 2030. The consolidation enhances their capabilities across the healthcare spectrum, targeting tech transfer, company creation, scale-ups, and growth-stage ventures in biopharma, medtech, and digital health. Previously, the two firms co-invested in ventures like Deepull and Ona Therapeutics, underscoring aligned investment philosophies. Under the new structure, the Alta Life Sciences Spain I FCR fund will be co-managed by Asabys and AltamarCAM Partners, aiming to maximize investor value and market reach.